Inositol hexaphosphate inhibits tumor growth, vascularity, and metabolism in TRAMP mice: A multiparametric magnetic resonance study

Cancer Prevention Research

Volumn 6, Issue 1, 2013, Pages 40-50

  Raina, Komal ^a   Ravichandran, Kameswaran ^a   Rajamanickam, Subapriya ^a   Huber, Kendra M ^b   Serkova, Natalie J ^b,c   Agarwal, Rajesh ^a,c  

^a Skaggs School of Pharmacy   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INOSITOL; MEMBRANE PHOSPHOLIPID; PHYTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GLUCOSE METABOLISM; MALE; METABOLISM; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE VOLUME; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR VASCULARIZATION; TUMOR VOLUME;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; BODY WEIGHT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE TRANSPORTER TYPE 4; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PHYTIC ACID; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872721962     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0387     Document Type: Article

References (50)

1. Gronberg H. Prostate cancer epidemiology. Lancet 2003; 361: 859-64. (Pubitemid 36331852)
2. Ko YJ, Bubley GJ. Prostate cancer in the older man. Oncology 2001; 15: 1113-31.
3. Bhatt RS, Bubley GJ. The challenge of herbal therapies for prostate cancer. Clin Cancer Res 2008; 14: 7581-2.
4. Brand TC, Canby-Hagino ED, Pratap Kumar A, Ghosh R, Leach RJ, Thompson IM. Chemoprevention of prostate cancer. Hematol Oncol Clin North Am 2006; 20: 831-43. (Pubitemid 44067400)
5. Singh RP, Agarwal R. Prostate cancer and inositol hexaphosphate: efficacy and mechanisms. Anticancer Res 2005; 25: 2891-903.
6. Vucenik I, Shamsuddin AM. Protection against cancer by dietary IP6 and inositol. Nutr Cancer 2006; 55: 109-25. (Pubitemid 44719624)
7. Fox CH, Eberl M. Phytic acid (IP6), novel broad spectrum anti-neo-plastic agent: a systematic review. Complement Ther Med 2002; 10: 229-34. (Pubitemid 36575399)
8. Jariwalla RJ. Rice-bran products: phytonutrients with potential applications in preventive and clinical medicine. Drugs Exp Clin Res 2001; 27: 17-26. (Pubitemid 32215892)
9. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexapho-sphate (IP6) and inositol: from laboratory to clinic. J Nutr 2003; 133: 3778S-84S. (Pubitemid 37392600)
10. Brown KH, Solomons NW. Nutritional problems of developing countries. Infectious Disease Clin N Am 1991; 5: 297-317.
11. Raboy V. The ABCs of low-phytate crops. Nat Biotechnol 2007; 25: 874-5. (Pubitemid 47236906)
12. Grases F, Simonet BM, Perello J, Costa-Bauza A, Prieto RM. Effect of phytate on element bioavailability in the second generation of rats. J Trace Elem Med Biol 2004; 17: 229-34. (Pubitemid 38520261)
13. Vucenik I, Yang GY, Shamsuddin AM. Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer. Carcinogenesis 1995; 16: 1055-8.
14. Grases F, Simonet BM, Vucenik I, Perello J, Prieto RM, Shamsuddin AM. Effects of exogenous inositol hexakisphosphate (InsP(6)) on the levels of InsP(6) and of inositol trisphosphate (InsP(3)) in malignant cells, tissues and biological fluids. Life Sci 2002; 71: 1535-46. (Pubitemid 34804586)
15. Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R. Inositol hexapho-sphate inhibits constitutive activation of NF-kappa B in androgen-independent human prostate carcinoma DU145 cells. Anticancer Res 2003; 23: 3855-61. (Pubitemid 37474334)
16. Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R. Inositol hexapho-sphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells. Neo-plasia 2004; 6: 646-59. (Pubitemid 39411101)
17. Gu M, Raina K, Agarwal C, Agarwal R. Inositol hexaphosphate down-regulates both constitutive and ligand-induced mitogenic and cell survival signaling, and causes caspase-mediated apoptotic death of human prostate carcinoma PC-3 cells. Mol Carcinog 2010; 49: 1-12.
18. Gu M, Roy S, Raina K, Agarwal C, Agarwal R. Inositol hexaphosphate suppresses growth and induces apoptosis in prostate carcinoma cells in culture and nude mouse xenograft: PI3K-Akt pathway as potential target. Cancer Res 2009; 69: 9465-72.
19. Raina K, Rajamanickam S, Singh RP, Agarwal R. Chemopreventive efficacy of inositol hexaphosphate against prostate tumor growth and progression in TRAMP mice. Clin Cancer Res 2008; 14: 3177-84.
20. Shamsuddin AM, Yang GY. Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. Carcinogenesis 1995; 16: 1975-9.
21. Singh RP, Agarwal C, Agarwal R. Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 2003; 24: 555-63. (Pubitemid 36432653)
22. Singh RP, Sharma G, Mallikarjuna GU, Dhanalakshmi S, Agarwal C, Agarwal R. In vivo suppression of hormone-refractory prostate cancer growth by inositol hexaphosphate: induction of insulin-like growth factor binding protein-3 and inhibition of vascular endothelial growth factor. Clin Cancer Res 2004; 10: 244-50. (Pubitemid 38114186)
23. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995; 92: 3439-43.
24. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003; 55: 219-37. (Pubitemid 36532401)
25. Oto A, Yang C, Kayhan A, Tretiakova M, Antic T, Schmid-Tannwald C, et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. Am J Roentgenol 2011; 197: 1382-90.
26. Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, et al. Overview of dynamic contrast-enhanced MRI in prostate cancer diagnosis and management. Am J Roentgenol 2012; 198: 1277-88.
27. Troiani T, Serkova NJ, Gustafson DL, Henthorn TK, Lockerbie O, Merz A, et al. Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res 2007; 13: 6450-8. (Pubitemid 350075035)
28. Degrassi A, Russo M, Scanziani E, Giusti A, Ceruti R, Texido G, et al. Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials. Prostate 2007; 67: 396-404. (Pubitemid 46341080)
29. Raina K, Rajamanickam S, Singh RP, Deep G, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2008; 68: 6822-30.
30. Klawitter J, Anderson N, Klawitter J, Christians U, Leibfritz D, Eckhardt SG, et al. Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR-profiling study. Br J Cancer 2009; 100: 923-31.
31. Raina K, Serkova NJ, Agarwal R. Silibinin feeding alters the metabolic profile in TRAMP prostatic tumors: 1H-NMRS-based metabolomics study. Cancer Res 2009; 69: 3731-5.
32. Serkova NJ, Niemann CU. Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics. Expert Rev Mol Diagn 2006; 6: 717-31. (Pubitemid 44525597)
33. Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, et al. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2007; 67: 11083-91. (Pubitemid 350145939)
34. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64: 2270-305. (Pubitemid 38339483)
35. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 2001; 61: 2736-43. (Pubitemid 32685863)
36. Ozawa MG, Yao VJ, Chanthery YH, Troncoso P, Uemura A, Varner AS, et al. Angiogenesis with pericyte abnormalities in a transgenic model of prostate carcinoma. Cancer 2005; 104: 2104-15. (Pubitemid 41579956)
37. Marti HH, Risau W. Systemic hypoxia changes the organ-specific distribution of vascular endothelial growth factor and its receptors. Proc Natl Acad Sci U S A 1998; 95: 15809-14. (Pubitemid 29018782)
38. Singh RP, Agarwal R. Inducible nitric oxide synthase-vascular endothelial growth factor axis: a potential target to inhibit tumor angiogenesis by dietary agents. Curr Cancer Drug Targets 2007; 7: 475-83. (Pubitemid 47196207)
39. Greten FR, Karin M. The IKK/NF-kappaB activation pathway - a target for prevention and treatment of cancer. Cancer Lett 2004; 206: 193-9. (Pubitemid 38317289)
40. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501. (Pubitemid 37328931)
41. Calvo MB, Figueroa A, Pulido EG, Campelo RG, Aparicio LA. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol 2010; 2010: 1-14.
42. Jiang W, Zhu Z, Thompson HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res 2008; 68: 5492-9.
43. Jansen M, Ten Klooster JP, Offerhaus GJ, Clevers H. LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev 2009; 89: 777-98.
44. Glunde K, Serkova NJ. Therapeutic targets and biomarkers identified in cancer choline phospholipid metabolism. Pharmacogenomics 2006; 7: 1109-23. (Pubitemid 44644788)
45. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004; 4: 551-61. (Pubitemid 38868624)
46. Serkova NJ, Gamito EJ, Jones RH, O'Donnell C, Brown JL, Green S, et al. The metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. Prostate 2008; 68: 620-8. (Pubitemid 351614640)
47. Pollack MN. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 2007; 86:s820-2.
48. Chen N, Ma WY, Dong Z. Inositol hexaphosphate inhibits ultraviolet B-induced signal transduction. Mol Carcinog 2001; 31: 139-44. (Pubitemid 32744533)
49. Huang C, Ma WY, Hecht SS, Dong Z. Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3' kinase. Cancer Res 1997; 57: 2873-8. (Pubitemid 27315031)
50. Jelluma N, Yang X, Stokoe D, Evan GI, Dansen TB, Haas-Kogan DA. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res 2006; 4: 319-30. (Pubitemid 43837333)